Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on CIM, JRCC, HOV and YMI Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2013
2013-01-21 14:49:02 -

NEW YORK, NY -- (Marketwire) -- 01/21/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Chimera Investment Corporation (NYSE: CIM) shares have rallied over 10 percent in the past month. The company currently offers investors an annual dividend of $0.36 per share for a dividend yield of approximately 12.3 percent.



Find out more about Chimera including full access to the free equity report at: www.BedfordReport.com/CIM : www.bedfordreport.com/CIM





James River Coal Company (NASDAQ: JRCC) shares surged 10 percent on over 2.5 million shares traded Friday. The International Energy Agency has recently predicted that by 2017 coal will rival oil as the world's top energy source.



Find out more about James River Coal including full access to the free equity report at: www.BedfordReport.com/JRCC : www.bedfordreport.com/JRCC



Hovnanian Enterprises, Inc. (NYSE: HOV) shares gained 5.8 percent on over 15 million shares traded Friday. The U.S. housing market recovery has continued in 2013 as U.S. home prices gained 7.4 percent year-over-year in November, the largest gain seen in 6.5 years.



Find out more about Hovnanian Enterprises including full access to the free equity report at: www.BedfordReport.com/HOV : www.bedfordreport.com/HOV



YM BioSciences Inc. (NYSE: YMI) (TSX: YM) is a drug development company primarily focused on advancing CYT38. The company has recently reported that proxy advisory firms Institutional Investor Services and Glass, Lewis & Co. have recommended that shareholders vote in favor of the Gilead deal.



Find out more about YM BioSciences including full access to the free equity report at: www.BedfordReport.com/YMI : www.bedfordreport.com/YMI



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=654368F5D7C96027



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser